Quality analysis of salmon calcitonin in a polymeric bioadhesive pharmaceutical formulation: sample preparation optimization by DOE.

A sensitive and selective HPLC method for the assay and degradation of salmon calcitonin, a 32-amino acid peptide drug, formulated at low concentrations (400 ppm m/m) in a bioadhesive nasal powder containing polymers, was developed and validated. The sample preparation step was optimized using Plackett-Burman and Onion experimental designs. The response functions evaluated were calcitonin recovery and analytical stability. The best results were obtained by treating the sample with 0.45% (v/v) trifluoroacetic acid at 60 degrees C for 40 min. These extraction conditions did not yield any observable degradation, while a maximum recovery for salmon calcitonin of 99.6% was obtained. The HPLC-UV/MS methods used a reversed-phase C(18) Vydac Everest column, with a gradient system based on aqueous acid and acetonitrile. UV detection, using trifluoroacetic acid in the mobile phase, was used for the assay of calcitonin and related degradants. Electrospray ionization (ESI) ion trap mass spectrometry, using formic acid in the mobile phase, was implemented for the confirmatory identification of degradation products. Validation results showed that the methodology was fit for the intended use, with accuracy of 97.4+/-4.3% for the assay and detection limits for degradants ranging between 0.5 and 2.4%. Pilot stability tests of the bioadhesive powder under different storage conditions showed a temperature-dependent decrease in salmon calcitonin assay value, with no equivalent increase in degradation products, explained by the chemical interaction between salmon calcitonin and the carbomer polymer.

[1]  A. Göpferich,et al.  Peptide acylation by poly(alpha-hydroxy esters). , 2002, Pharmaceutical research.

[2]  C. Van de Wiele,et al.  Quality specifications for peptide drugs: a regulatory‐pharmaceutical approach , 2009, Journal of peptide science : an official publication of the European Peptide Society.

[3]  L Silvestro,et al.  High-performance liquid chromatography/tandem mass spectrometry identification of salmon calcitonin degradation products in aqueous solution preparations. , 1996, Rapid communications in mass spectrometry : RCM.

[4]  F. Deluccia,et al.  Degradation pathways of salmon calcitonin in aqueous solution. , 1997, Journal of pharmaceutical sciences.

[5]  L. Deftos Two-site immunoradiometric assay of intact salmon calcitonin. , 1992, Clinical chemistry.

[6]  W. Nelp,et al.  Long-term calcitonin therapy in postmenopausal osteoporosis. , 1984, Metabolism: clinical and experimental.

[7]  D. Copp,et al.  Calcitonin—a Hormone from the Parathyroid which Lowers the Calcium-level of the Blood , 1962, Nature.

[8]  G. Walker,et al.  Carbomer Inhibits Tryptic Proteolysis of Luteinizing Hormone-Releasing Hormone and N-α-Benzoyl-L-Arginine Ethyl Ester by Binding the Enzyme , 1999, Pharmaceutical Research.

[9]  S. Wimalawansa,et al.  Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. , 1997, Critical reviews in neurobiology.

[10]  C Vervaet,et al.  Effect on the nasal bioavailability of co-processing drug and bioadhesive carrier via spray-drying. , 2009, International journal of pharmaceutics.

[11]  D. Copp,et al.  Evidence for calcitonin--a new hormone from the parathyroid that lowers blood calcium. , 1962, Endocrinology.

[12]  C. Shim,et al.  Simple liquid chromatography-electrospray ionization mass spectrometry method for the routine determination of salmon calcitonin in serum. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[13]  M. Gümüşderelioğlu,et al.  Release characteristics of salmon calcitonin from dextran hydrogels for colon-specific delivery. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[14]  T. Buclin,et al.  Bioavailability and Biological Efficacy of a New Oral Formulation of Salmon Calcitonin in Healthy Volunteers , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  Manuel Muñoz-Torres,et al.  Calcitonin Therapy in Osteoporosis , 2004, Treatments in endocrinology.

[16]  Chong-K. Kim,et al.  Post-column fluorescence HPLC for salmon calcitonin formulations , 1995 .

[17]  C. K. Jeong,et al.  Determination of salmon calcitonin in formulations by high-performance liquid chromatography with electrochemical detection , 1999 .

[18]  L. Deftos,et al.  Two-site immunofluorometric assay of intact salmon calcitonin with improved sensitivity. , 1997, Clinical chemistry.

[19]  D. H. Copp,et al.  25 Years of salmon calcitonin: From synthesis to therapeutic use , 1995, Calcified Tissue International.

[20]  J. Remon,et al.  Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine. , 2009, Vaccine.

[21]  A. Göpferich,et al.  Peptide Acylation by Poly(α-Hydroxy Esters) , 2002, Pharmaceutical Research.

[22]  M. Horowitz,et al.  Amylin , 2006 .

[23]  G D Roodman,et al.  Cell biology of the osteoclast. , 1999, Experimental hematology.

[24]  S. Chae,et al.  Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[25]  J. Gaddum,et al.  United States Pharmacopeia , 1955, Nature.

[26]  R. Mumper,et al.  Buccal Transmucosal Delivery of Calcitonin in Rabbits Using Thin-Film Composites , 2002, Pharmaceutical Research.

[27]  S. Neau,et al.  Extruded and spheronized beads containing Carbopol 974P to deliver nonelectrolytes and salts of weakly basic drugs. , 2006, International journal of pharmaceutics.

[28]  Kang-Choon Lee,et al.  Degradation of Synthetic Salmon Calcitonin in Aqueous Solution , 1992, Pharmaceutical Research.

[29]  N. Peppas,et al.  Transmucosal delivery systems for calcitonin: a review. , 2000, Biomaterials.